Biotechnology News and Research

RSS

Childhood cognitive ability linked to cognitive ability, cortical thickness in old age

A new study shows compelling evidence that associations between cognitive ability and cortical grey matter in old age can largely be accounted for by cognitive ability in childhood.

5 Jun 2013

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

4 Jun 2013

Mid-Atlantic Crossroads announces launch of Double HELIX

Mid-Atlantic Crossroadsannounces the launch of Double HELIX (Health, Education, Life Sciences, and Internet eXchange), the new high-performance point of presence located at the Institute for Bioscience and Biotechnology Research in Rockville, Maryland.

4 Jun 2013

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration.

3 Jun 2013

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Amgen today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

3 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Plants to teach robots how to work together

John Innes Centre scientists will participate in new -2 million EU-funded research to programme more "intelligent" and adaptable robot swarms.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Comprehensive analyses of the benefits and risks of NSAIDs

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of The Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs, which include cyclo-oxygenase-2 inhibitors (coxibs).

31 May 2013

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Doctors at the Texas Heart Institute at St. Luke's Episcopal Hospital announced that they have performed an investigational procedure on six patients in a new FDA-approved clinical trial to evaluate therapy that uses regenerative cells derived from a patient's own adipose (body fat) tissue to treat a severe form of heart failure.

30 May 2013

Scientists develop new chemical method to treat Alzheimer's disease

Scientists at the University of Liverpool and Callaghan Innovation in New Zealand have developed a new chemical approach to help harness the natural ability of complex sugars to treat Alzheimer's disease.

30 May 2013

Standalone labelling service announced by Packaging Coordinators Inc (PCI)

Packaging Coordinators Inc (PCI), formerly AndersonBrecon, a global supplier of pharmaceutical commercial packaging solutions and clinical trials services, today announced a standalone labelling service that can dramatically reduce design and printing turnaround times. The fast response labelling solution has been developed to meet the ever-evolving needs of customers in the industry, providing bespoke, around-the-clock support and ensuring that even projects where labelling requirements change unexpectedly are successfully kept on track.

From Packaging Coordinators Inc. (PCI) 29 May 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Asfotase alfa gets Breakthrough Therapy designation from FDA for treatment of patients with HPP

Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to asfotase alfa for the treatment of patients with hypophosphatasia (HPP) whose first signs or symptoms occurred prior to 18 years of age, including perinatal-, infantile-, and juvenile-onset forms of the disease.

28 May 2013

Biotechnology News and Research

Childhood cognitive ability linked to cognitive ability, cortical thickness in old age

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Mid-Atlantic Crossroads announces launch of Double HELIX

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Plants to teach robots how to work together

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

GLYX-13 drug induces antidepressant results without street drug side effects

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Comprehensive analyses of the benefits and risks of NSAIDs

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Doctors perform investigational procedure on six patients using ADRCs to treat heart failure

Scientists develop new chemical method to treat Alzheimer's disease

Standalone labelling service announced by Packaging Coordinators Inc (PCI)

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Asfotase alfa gets Breakthrough Therapy designation from FDA for treatment of patients with HPP

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News